Skip to main content

Table 5 Univariate (5a) and multivariate analysis (5b) for PFS and OS

From: Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma

   

  PFS

 

  OS

 
 

n risk

n events

1 year-PFS (%) (± SE)

p

1 year-OS (%) (± SE)

p

a

      

PS

      

0–1

22

21

50 ± 10.7

0.001

63.6 ± 10.3

0.006

2–3

8

7

0

 

15.6 ± 14.2

 

Age

      

≤68 years

15

14

58.2 ± 13.1

0.06

79.4 ± 10.6

0.017

>68 years

15

14

20 ± 10.3

 

26.7 ± 11.4

 

Sex

      

M

19

18

31.8 ± 14.9

0.3

52.6 ± 11.5

0.4

F

11

10

42.1 ± 11.3

 

60.6 ± 15.4

 

Group 1

24

22

31.1 ± 9.7

0.17

44 ± 10.4

0.11

Group 2

6

6

66.7 ± 19.2

 

83.3 ± 15.2

 

T stage

      

T1-2

3

2

66.7 ± 27.2

0.2

66.6 ± 27.2

0.25

T3-4

18

17

18.3 ± 9.5

 

35.9 ± 11.7

 

N stage

      

N0

11

9

31.8 ± 14.9

0.8

41.6 ± 15.6

0.7

N1

11

11

27.3 ± 13.4

 

45.5 ± 15

 

Bismuth

      

I-II

9

8

33.3 ± 15.7

0.9

44.4 ± 16.6

0.6

III-IV

15

14

29.3 ± 12.2

 

43.3 ± 13.3

 

Tumor size ≤ 36 mm

12

10

27.8 ± 13.6

0.8

36.7 ± 14.6

0.3

>36 mm

9

9

33.3 ± 15.7

 

55.6 ± 16.6

 

Chemotherapy

     

0.15

Yes

18

18

44.4 ± 11.7

0.3

66.7 ± 11.1

No

12

10

28.6 ± 13.8

 

27.5 ± 13.5

b

  
 

  PFS

 

  OS

 

factors

HR [CI95%]

p

HR [CI95%]

p

PS 0–1 vs 2-3

3.9 [1.4-11.1]

0.01

3.9 [1.4-10.9]

0.01

Age ≤68 years vs >68 years

1.5 [0.56-4]

0.4

4.9 [1.2-18.9]

0.02

Group 1 vs 2

0.7 [0.2-2.3]

0.6

0.8 [0.2-2.]

0.7

Chemotherapy yes vs no

_

_

2.4 [0.7-8.2]

0.16

  1. Abbreviations: PS, performance status; SE standard error; T stage and N stage according to TNM classification; Bismuth: Bismuth classification; vs: versus; CI 95%: 95% Confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us